GBB Maintains Strong Position in its Ongoing Lawsuit with FSD Pharma After Court Refuses to Dismiss Case
11 Janeiro 2024 - 3:10PM
GBB Drink Lab. Inc (“GBB” or the “Company”), a maker of the world’s
first rapid blood alcohol detoxification beverage, is pleased to
announce that a federal court has refused to dismiss the Company’s
ongoing lawsuit against FSD Pharma.
FSD Pharma (NASDAQ: HUGE), a clinical-stage biotech company, has
violated a Non-Disclosure Agreement (NDA) with GBB and has breached
the contract by attempting to steal information and launch GBB’s
product without permission.
"Nowhere in the Amended Complaint does Plaintiff allege that all
nineteen of the ingredients are necessary to create a parallel
program or competitor drink, and this Court sees no reason to
impose such a requirement. It is apparent, at least to this Court,
that Plaintiff takes issue with Defendants’ development of a
competing drink, which relies on most of the same ingredients (and
methods for combining such ingredients) as Plaintiff’s proprietary
beverage,” said the Court.
The Court added, “Drawing all inferences in Plaintiff’s favor,
this Court concludes that Plaintiff has sufficiently demonstrated
that its trade secrets derived economic value from not being
readily ascertainable by others. Plaintiff alleges that the
unidentified investors pulled out of the contemplated deals
“because of Defendants’ announcements (and the promotional content)
related to the development and planned future launch of a competing
product that utilizes GBB’s confidential information.”
The Court’s decision not to dismiss the case represents a major
victory for the Company and GBB is aggressively continuing legal
action against the theft of their confidential information and to
stop FSD Pharma from launching their product.
“The Court’s decision to not dismiss our case demonstrates that
we have a strong legal position based on the facts. We look forward
to a full and fair proceeding to resolve this matter and we believe
that we will be victorious,” said GBB CEO John Gulyas.
About GBB Drink LabGBB Drink Lab started with a
vision of making a positive impact by offering practical,
evidence-based solution to reducing Blood Alcohol Content. The
company’s product has been meticulously crafted to optimize your
ability to reduce the effects of alcohol to escape an inebriated
state. GBB Drink Lab leadership team includes accomplished serial
entrepreneurs, a former senior executive from one of the world’s
largest beverage companies, and an industry leading expert in
flavoring science and product formulation.
Media Contact:
Phone: 602-456-1555 Email info@gbbdrinklab.com
FSD Pharma (NASDAQ:HUGE)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
FSD Pharma (NASDAQ:HUGE)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025